All In Biotech

Drug Trial Radar · NCT02616146

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)

A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contraceptive (COC) in Healthy Women 18 Years of Age and Older, at Risk for Pregnancy.

Last checked: Nov 19, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,016 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,016

Actual

Start

Dec 1, 2015

Primary completion

Oct 6, 2016

Study completion Oct 6, 2016

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Nov 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the contraceptive efficacy of the etonogestrel + 17β-estradiol (ENG-E2) vaginal ring in women between 18 and 35 years of age based on the number of in-treatment pregnancies as expressed by the Pearl Index (PI). The study will also assess the safety and tolerability of ENG-E2 vaginal ring. The levonorgestrel-ethinyl estradiol (LNG-EE) 150/30 μg combined oral contraceptive (COC) will be used as the active comparator.

Conditions

  • Contraception

Interventions

  • ENG-E2 125 μg/300 μg vaginal ringDrug

    Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.

  • LNG-EE 150 μg/30 μg COCDrug

    Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)Time frame: Up to 1 year (13 28-day cycles)
  2. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to 1 year
  3. Number of Participants Who Discontinued Treatment Due to an AETime frame: Up to 1 year

Locations

14 sites in 14 countries. Site status is shown where the registry gives one.

  • MSD Osterreich GmbH

    Vienna, Austria

  • Merck Sharp & Dohme

    San José, Costa Rica

  • Merck Sharp & Dohme

    Glostrup Municipality, Denmark

  • MSD Finland Oy

    Espoo, Finland

  • Merck Sharp & Dohme GmbH

    Haar, Germany

  • MSD Pharma Hungary Kft.

    Budapest, Hungary

  • MSD Italia S.r.l.

    Rome, Italy

  • MSD

    Mexico City, Mexico

  • Merck Sharp & Dohme BV

    Haarlem, Netherlands

  • MSD Norge A/S

    Drammen, Norway

  • Merck Sharp & Dohme, Peru S.R.L.

    Lima, Peru

  • MSD Polska Sp. Z o.o.

    Warsaw, Poland

  • MSD (Pty) LTD South Africa

    Midrand, South Africa

  • MSD Sweden

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.